Aquestive Therapeutics, Inc. AQST
Set alert
As of Nov 3, 10:13 AM ET
- YTD
- -39.32%
- 1 year
- -39.60%
- Open
- 3.78
- Prev close
- 3.77
- Mkt cap
- 491.98M
- Vol
- 179.91K
- Avg vol
- 2.74M
- EPS
- -0.66
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.78
- High
- 3.94
- Forward P/E
- -5.87
- Beta
- 2.82
- Short ratio
- 6.37
- Inst. own
- 55.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 4.68
- 200-d avg
- 4.02
- 1y target
- 10.83
5D chart
Signals (56)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 3:55 PM | 18 hours ago |
| RSI: Overbought | Nov 2, 3:10 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 2:40 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 2:40 PM | 19 hours ago |
| MACD: Buy Signal | Nov 2, 2:40 PM | 19 hours ago |
| MACD: Sell Signal | Nov 2, 2:25 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 1:40 PM | 20 hours ago |
| SMA: Bearish | Nov 2, 12:50 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 12:25 PM | 21 hours ago |
| SMA: Bearish | Nov 2, 12:15 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 12:10 PM | 22 hours ago |
| MACD: Buy Signal | Nov 2, 12:10 PM | 22 hours ago |
| MACD: Sell Signal | Nov 2, 12:05 PM | 22 hours ago |
| MACD: Buy Signal | Nov 2, 12:00 PM | 22 hours ago |
| RSI: Oversold | Nov 2, 11:40 AM | 22 hours ago |
| RSI: Oversold | Nov 2, 10:35 AM | 23 hours ago |
| MACD: Sell Signal | Nov 2, 10:05 AM | 1 day ago |
| SMA: Bearish | Nov 2, 9:50 AM | 1 day ago |
| SMA: Bearish | Nov 2, 9:50 AM | 1 day ago |
| SMA: Bullish | Nov 2, 9:45 AM | 1 day ago |
Newest 20 of 56.
News
1 week ago globenewswire.com
Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful…
2 weeks ago defenseworld.net
Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $105,500.00 in Stock
Aquestive Therapeutics, Inc. (NASDAQ: AQST - Get Free Report) CEO Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock in a transaction that occurred on Thursday, October 15th. The shares…
2 weeks ago seekingalpha.com
Aquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating Upgrade
Aquestive Therapeutics received FDA acceptance for the Anaphylm NDA resubmission, targeting a March 16, 2027 PDUFA date. Resubmission addresses prior FDA concerns with improved human factors data,…
-
2 weeks ago benzinga.com
FDA Accepts Aquestive Therapeutics’ Anaphylm NDA Resubmission; PDUFA Goal Action Date Set For March 16, 2027
FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027Ex-U.S. strategy remains on track with…
2 weeks ago globenewswire.com
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful…
2 weeks ago benzinga.com
Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug
Eton Pharmaceuticals licenses Aquestive’s LIBERVANT buccal film for U.S. seizure cluster treatment, with launch set for April 2027.
-
2 weeks ago benzinga.com
Eton Pharmaceuticals And Aquestive Therapeutics Enter Exclusive U.S. License And Supply Agreement For LIBERVANT Buccal Film For Seizure Clusters In Patients With Epilepsy; Sees Commercial Availability In April 2027
Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually…
3 weeks ago prnewswire.com
Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop
SAN FRANCISCO, Oct. 7, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Aquestive Therapeutics, Inc. (Nasdaq: AQST) investors that the firm is investigating potential legal claims arising…
1 month ago globenewswire.com
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to…
1 month ago defenseworld.net
Aquestive Therapeutics, Inc. $AQST Shares Sold by Squarepoint Ops LLC
Squarepoint Ops LLC reduced its position in Aquestive Therapeutics, Inc. (NASDAQ: AQST) by 71.8% in the undefined quarter, according to its most recent filing with the Securities and Exchange…
1 month ago benzinga.com
Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy Treatment
Aquestive Therapeutics has resubmitted its New Drug Application to the FDA for Anaphylm, a sublingual film for severe allergic reactions.
1 month ago globenewswire.com
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026 FDA will determine the resubmission classification and establish the…
2 months ago defenseworld.net
8,069,373 Shares in Aquestive Therapeutics, Inc. $AQST Acquired by BlackRock Inc.
BlackRock Inc. bought a new position in Aquestive Therapeutics, Inc. (NASDAQ: AQST) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The…
2 months ago globenewswire.com
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful…
2 months ago defenseworld.net
AWM Investment Company Inc. Takes $1.98 Million Position in Aquestive Therapeutics, Inc. $AQST
AWM Investment Company Inc. purchased a new position in Aquestive Therapeutics, Inc. (NASDAQ: AQST) in the undefined quarter, according to the company in its most recent Form 13F filing with the…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Buy and maintains $10 price target.
2 months ago seekingalpha.com
Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript
Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Aquestive Therapeutics Q2 Earnings Call Highlights
Aquestive Therapeutics NASDAQ: AQST said it plans to resubmit its new drug application for Anaphylm, its epinephrine sublingual film candidate for type 1 allergic reactions including anaphylaxis,…
2 months ago zacks.com
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.14 per share a year ago.
-
2 months ago benzinga.com
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $50.584M Est
Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 million to $46.000 million-$50.000 million vs $50.584 million estimate.
2 months ago globenewswire.com
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful…
2 months ago benzinga.com
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study
Aquestive Therapeutics Inc. (NASDAQ:AQST) announced positive findings from human factors and pharmacokinetic validation studies for its Anaphylm (dibutepinephrine) sublingual film.
2 months ago benzinga.com
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study
Aquestive Therapeutics reports positive study results for Anaphylm sublingual film, paving the way for a Q3 FDA resubmission.
2 months ago benzinga.com
Varex Imaging Posts Upbeat Q3 Earnings, Joins Bowman Consulting, MarineMax And Other Big Stocks Moving Higher On Monday
BWMN gained 55.1%, HZO rose 45.8%, ABCL gained 35.6%, SLN rose 34.3%, ACHR gained 19.5%, NESR gained 16.4%, AQST gained 15.4%, STDN rose 13.7%.
2 months ago globenewswire.com
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
Human factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third quarter of 2026 Self-administration pharmacokinetic (PK) results were comparable to…
3 months ago globenewswire.com
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful…
3 months ago globenewswire.com
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
WARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement…
4 months ago zacks.com
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in…
5 months ago benzinga.com
Staar Surgical Posts Upbeat Q1 Results, Joins Cisco, Yeti Holdings And Other Big Stocks Moving Higher On Thursday
U.S. stocks rose, with Dow Jones up 300 points. STAA shares surged after better-than-expected results. Other big gainers include POET, STUB, MSC, ARX, CSCO, PCT, WOLF, CPA, ONDS, KLAR, and RDW.
5 months ago benzinga.com
Aquestive Therapeutics Q1 2026 Earnings Call: Complete Transcript
Aquestive Therapeutics Q1 2026 Earnings Call: Complete Transcript
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
5 months ago benzinga.com
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $48.072M Est
Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 million to $46.000 million-$50.000 million vs $48.072 million estimate.
-
5 months ago benzinga.com
Aquestive Therapeutics Q1 EPS $(0.07) Beats $(0.15) Estimate, Sales $14.446M Beat $10.896M Estimate
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.15) by 53.33 percent. This is a 70.83 percent increase over losses…
-
7 months ago benzinga.com
Aquestive Therapeutics Completes In-Person Type A Meeting With FDA Regarding Resubmission Of NDA For Anaphylm Sublingual Film For Treatment Of Type 1 Allergic Reactions, Including Anaphylaxis
Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science…
8 months ago benzinga.com
Aquestive Therapeutics Q4 Earnings Assessment
Aquestive Therapeutics Q4 Earnings Assessment
-
8 months ago benzinga.com
Aquestive Therapeutics Sees FY2026 Sales $46.000M-$50.000M vs $49.888M Est
Aquestive Therapeutics (NASDAQ:AQST) sees FY2026 sales of $46.000 million-$50.000 million vs $49.888 million analyst estimate.
-
8 months ago benzinga.com
Aquestive Therapeutics Q4 Adj. EPS $(0.15) Misses $(0.13) Estimate, Sales $13.015M Miss $13.284M Estimate
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.13) by 12.78 percent. This is a 21.05 percent increase over…
-
8 months ago benzinga.com
A Preview Of Aquestive Therapeutics's Earnings
A Preview Of Aquestive Therapeutics's Earnings
9 months ago benzinga.com
What Does the Market Think About Aquestive Therapeutics Inc?
What Does the Market Think About Aquestive Therapeutics Inc?
9 months ago benzinga.com
What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment?
Aquestive received an FDA rejection for its allergy film due to safety and use issues. The company plans new studies and targets resubmission in 2026.
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
9 months ago benzinga.com
Peakstone Realty Trust, Aquestive Therapeutics, Opera And Other Big Stocks Moving Higher On Monday
Peakstone Realty Trust, Aquestive Therapeutics, Opera And Other Big Stocks Moving Higher On Monday
-
9 months ago benzinga.com
Aquestive Therapeutics Receives CRL From FDA For NDA Seeking Approval Of Anaphylm Sublingual Film For Treatment Of Type I Allergic Reactions, Including Anaphylaxis, In Patients Weighing 30kg Or More
Deficiencies limited to packaging and administration Company believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3 2026 Remains well-capitalized and anticipates ending…
-
9 months ago benzinga.com
Peering Into Aquestive Therapeutics Inc's Recent Short Interest
Peering Into Aquestive Therapeutics Inc's Recent Short Interest
9 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session
9 months ago benzinga.com
Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
9 months ago benzinga.com
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock
ARS Pharmaceuticals Inc. stock rose Friday as FDA identified deficiencies in rival Aquestive's application, delaying potential competition.
9 months ago benzinga.com
Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January
Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January